INNA-051
From Wikipedia, the free encyclopedia
Vaccine candidate against COVID-19
Pharmaceutical compound
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Routes of administration | Intranasal |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg){kind=small} COVID-19 portal |
INNA-051 is a COVID-19 vaccine candidate developed by Ena Respiratory.[1][2]
- ↑ "INNA-051 intranasal safety and tolerability study". anzctr.org.au. 21 April 2021. ACTRN12621000607875p. Retrieved 20 May 2021.
- ↑ Clinical trial number NCT05118763 for "Intranasal INNA-051 for Prevention of COVID-19 in Adults" at ClinicalTrials.gov
Scholia has a profile for INNA-051 (Q110269792).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |